VGXI: DNA Science
Global Capabilities Series: Insights from CGT Asia 2025
Interview with Jeff Whitmore, Chief Commercial Officer, on VGXI’s Role in Bridging APAC Innovation and U.S. Commercialization As part of our ongoing commitment to international[...]
Read More
Future Proof Your Advanced Therapies Supply Chain with VGXI’s US-Based Plasmid CDMO Expertise
In the current landscape of biopharmaceutical drug development, finding a reliable and experienced contract development and manufacturing organization (CDMO) partner is a strategic advantage that[...]
Read More
Five Qualities to Look for in a CDMO
As the biopharmaceutical industry increasingly turns to outsourcing, the key to success lies in choosing the right Contract Development and Manufacturing Organization (CDMO). A trusted[...]
Read More
VGXI’s Full Spectrum Plasmid DNA Solutions: From Discovery to Commercialization
Plasmids are small, circular, double-stranded DNA molecules that have become indispensable tools in the life sciences. They are primarily found in bacteria and are capable[...]
Read More
An Introduction to DNA and Vaccines
Vaccines are one of humanity’s most important inventions as they help protect public health and save millions of lives every year. By stimulating the body’s[...]
Read More
VGXI Partner IMM Announces $12M NIH Grant to Support Phase 1 Clinical Trial of a DNA Vaccine for the Prevention of Alzheimer’s Disease
Texas-based CDMO VGXI, Inc. is excited to announce that its partner, The Institute for Molecular Medicine, has recently been awarded a $12 million NIA grant[...]
Read More